By John Vandermosten, CFANASDAQ:LPCNLipocine (NASDAQ:LPCN) published two press releases in the last two weeks signaling the advancement of LPCN 1144 towards a Phase II trial in non-alcoholic steatohepatitis (NASH) with biopsy confirmed NASH subjects. Yesterday, Lipocine announced meaningful liver fat reduction in patients participating in its study accompanied by...
By Brian Marckx, CFANASDAQ:MYOSREAD THE FULL MYOS RESEARCH REPORTPositive Results of Canine Muscle Recovery Study Following Surgery…Last week MYOS RENS Technology Inc (NASDAQ:MYOS) announced positive results of a study conducted at Kansas St. University evaluating the ability of their canine Fortetropin formula to reduce muscle loss in dogs following...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdateNo Cardiovascular Toxicity Concerns for VK2809Following release of the Phase 2 data for VK2809 in patients with hypercholesterolemia and nonalcoholic fatty liver disease (NAFLD), which we believe show the potential for VK2809 to be a best-in-class treatment in NAFLD and...
By Brian Marckx, CFANASDAQ:GNMXREAD THE FULL GNMX RESEARCH REPORTASCEND Misses Primary Endpoint: GNMX indicates they are not giving up in AEVI-001On January 2nd Aevi (NASDAQ:GNMX) announced that ASCEND, the phase II trial evaluating their non-stimulant glutamatergic neuromodulator in pediatric and adolescent subjects with ADHD, failed to meet its primary...
By Brian Marckx, CFANASDAQ:BMRAREAD THE FULL BMRA RESEARCH REPORTBiomerica’s IgG Antibody Test Used to Significantly Reduce Ulcerative Colitis Symptoms, Improve QoLResults of an n=97 randomized, investigator-blinded food-exclusion study showed that Biomerica’s (NASDAQ:BMRA) first-generation ELISA immunoglobulin G (IgG) antibody assay was able to significantly reduce ulcerative colitis symptoms and improve...
By Brian Marckx, CFANASDAQ:NAOVREAD THE FULL NAOV RESEARCH REPORTZacks SCR Senior Med-Tech analyst and Director of Research Brian Marckx, CFA has initiated coverage of NanoVibronix, Inc. with a $9.00/share price target. See below for free access to his 29-page report on the company.SNAPSHOTNanoVibronix, Inc. (NASDAQ:NAOV), develops, manufactures and commercializes...
By Anita Dushyanth, PhDNYSE:NNVCREAD THE FULL NNVC RESEARCH REPORTINITIATING COVERAGENanoViricides, Inc. (NYSE:NNVC) is an early stage nano-pharmaceutical company that was first listed in 2005 and became a reporting company the following year. The company is involved in discovering and developing therapeutics for treating viral infections with drug candidates in...
By David Bautz, PhDTSX:ATE.VREAD THE FULL ATE.V RESEARCH REPORTFinancial UpdateOn December 19, 2018, Antibe Therapeutics, Inc. (TSX:ATE.V) announced a warrant exercise of nearly all outstanding warrants with an expiration date in December 2018 that resulted in gross proceeds to the company of approximately CAD$1.6 million. A total of 7,066,001...
By Brian Marckx, CFANASDAQ:DRRXREAD THE FULL DRRX RESEARCH REPORTPipeline UpdateEarlier this week Durect (NASDAQ:DRRX) provided a corporate and pipeline update. Much of the focus was, as expected, on DUR-928. Particularly noteworthy is that the company announced a somewhat updated strategy as it relates to DUR-928 - specifically that they...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateTreatment with Exebacase Beneficial to S. Aureus Bacteremia PatientsOn January 7, 2019, ContraFect Corp. (NASDAQ:CFRX) announced topline results from the Phase 2 trial of exebacase (CF-301) in patients with bacteremia caused by Staphylococcus aureus, including those with endocarditis. This was...